Targeted protein degradation (TPD) technologies are advancing to tackle extracellular proteins, expanding their therapeutic potential beyond intracellular targets. This development is crucial for addressing diseases driven by membrane-bound or secreted factors, such as neurodegeneration and inflammation, offering new treatment options for previously hard-to-drug targets.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





